Home › Asthma › NCT06935084
ASTHMAXcel Voice Study
Conducting a Randomized Controlled Trial for A Novel Patient-Facing Mobile Platform to Collect and Implement Patient-Reported Outcomes and Voice Biomarkers in Underserved Adult Patients With Asthma
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * English speaking * Persistent asthma (diagnosed by a healthcare provider) on a daily controller medication * Able to provide informed consent * Smartphone access (iOS or Android) with data plan Exclusion Criteria: * Pregnancy * Severe psychiatric or cognitive problems that would prohibit completion of protocol
About the study
The objective of this study is to conduct a randomized controlled trial (RCT) to compare the adapted and refined ASTHMAXcel Voice platform to usual care (UC). It is hypothesized by the investigator team that ASTHMAXcel Voice will be associated with improved clinical and process outcomes, asthma quality of life (QOL), medication adherence, and self-efficacy as compared to UC.
What is being tested
- ASTHMAXcel Voice platform (other)
Sponsor: Montefiore Medical Center · Participants: 200 · Started: Sep 18, 2025
Contact the study team
- Sunit Jariwala, MD · Phone: 609-937-1023
- Juliana D Rodriguez, MD · Phone: 718-862-1722
Official record on ClinicalTrials.gov — NCT06935084
Locations in the U.S.
| New York | Montefiore Medical Center, The Bronx |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.